Alibaba Health Information Technology (0241) AI Stock Analysis

• Market Cap: $88.01B
• Dividend Yield: N/A
• Average Volume (3M): 124.46M
• Price to Earnings (P/E): 56.7
• Beta (1Y): 2.16
• Revenue Growth: 12.02%
• EPS Growth: 40.17%
• Country: HK
• Employees: 1,422
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 0.07
• Shares Outstanding: 16,123,642,000
• 10 Day Avg. Volume: 136,634,638
• 30 Day Avg. Volume: 124,461,569
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.76
• Enterprise Value/Revenue: 4.39
• Enterprise Value/Gross Profit: 18.09
• Enterprise Value/Ebitda: 90.51
• 1Y Price Target: $6.78
• Price Target Upside: 24.25% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

• Rating: 73 Outperform
• Price Target: HK$6.50 ▲(19.05% Upside)

Alibaba Health Information Technology's strong financial performance is the primary driver of its stock score, supported by robust revenue and profit growth, and efficient cash flow management. The technical analysis indicates a strong upward trend, although overbought signals suggest caution. The high P/E ratio reflects overvaluation concerns, which slightly dampen the overall score.

Alibaba Health Information Technology Business Overview & Revenue Model

Company Description

Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. It offers range of prescription drugs, over-the-counter drugs, nutritional supplements, medical devices, contact lenses, and various other health-related products through its online stores on Tmall.com and offline pharmacy outlets to business-to-customer and business-to-business customers; and pharmaceutical products, medical devices and healthcare products, health food, sexual health and family planning products, contact lenses, and medical and healthcare services through its e-commerce platform. The company also provides medical and healthcare services, including medical checkups, nucleic acid testing, medical consultation, registration, vaccination, and TCM through various channels, such as Taobao, Tmall, Alipay, Dr. Deer APP, Gaode, DingTalk, and Quark. In addition, it engages in the tracking business; provision of network hospital, healthcare related internet information, internet information, and healthcare related technical services; operation of internet hospitals; and asset management services. The company was formerly known as CITIC 21CN Company Limited and changed its name to Alibaba Health Information Technology Limited in September 2014. Alibaba Health Information Technology Limited is based in Causeway Bay, Hong Kong.

How the Company Makes Money

Alibaba Health generates revenue through multiple streams, primarily from its online healthcare services, which include e-pharmacy sales, telemedicine consultations, and health management services. The company earns money by taking a commission on healthcare transactions facilitated through its platform, as well as through subscription fees from healthcare providers utilizing its health information systems. Additionally, partnerships with hospitals and pharmaceutical companies help to expand its service offerings and reach, contributing to its earnings. The growing trend of digital health solutions, especially in response to the COVID-19 pandemic, has further bolstered its revenue potential as more consumers and healthcare providers adopt these technologies.

Alibaba Health Information Technology Financial Statement Overview

Summary

Alibaba Health Information Technology shows strong financial health with impressive revenue and profit growth, efficient cost management, and robust cash flow generation. The company's low leverage and strong equity position further enhance its financial stability.

Income Statement

Alibaba Health Information Technology has demonstrated strong revenue growth with a 7.95% increase in the latest year. The gross profit margin has improved to 24.29%, indicating effective cost management. Net profit margin also increased to 4.68%, reflecting enhanced profitability. The EBIT and EBITDA margins have shown positive trends, suggesting operational efficiency improvements.

Balance Sheet

The company maintains a very low debt-to-equity ratio of 0.0022, indicating minimal leverage and financial risk. Return on equity has improved to 8.78%, showcasing effective use of shareholder funds. The equity ratio stands at a healthy level, reflecting a strong capital structure.

Cash Flow

Free cash flow growth has surged by 90.49%, highlighting robust cash generation capabilities. The operating cash flow to net income ratio is 0.29, indicating solid cash flow relative to earnings. The free cash flow to net income ratio is nearly 1, demonstrating efficient conversion of earnings into cash.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	15.30B	30.60B	27.03B	26.76B	20.58B	15.52B
Gross Profit	3.72B	7.43B	5.90B	5.70B	4.11B	3.62B
EBITDA	742.87M	1.62B	999.05M	-24.48M	-188.12M	52.14M
Net Income	716.21M	1.43B	883.48M	535.65M	-265.56M	348.59M
Balance Sheet
Total Assets	21.18B	21.18B	19.71B	20.75B	19.20B	17.74B
Cash, Cash Equivalents and Short-Term Investments	8.10B	8.10B	9.55B	10.92B	10.55B	11.64B
Total Debt	35.52M	35.52M	82.17M	77.80M	135.41M	37.74M
Total Liabilities	4.87B	4.87B	5.19B	5.60B	5.13B	3.46B
Stockholders Equity	16.31B	16.31B	14.54B	15.17B	14.10B	14.30B
Cash Flow
Free Cash Flow	697.52M	1.38B	1.06B	250.08M	409.43M	992.35M
Operating Cash Flow	697.52M	1.40B	1.08B	255.69M	424.36M	1.01B
Investing Cash Flow	-1.30B	-2.60B	-4.88B	-532.44M	1.87B	-4.96B
Financing Cash Flow	-36.26M	-72.52M	-1.98B	-111.28M	-58.63M	8.92B

Alibaba Health Information Technology Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.46
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0241, the sentiment is Positive. The current price of 5.46 is above the 20-day moving average (MA) of 5.26, above the 50-day MA of 4.86, and above the 200-day MA of 4.51, indicating a bullish trend. The MACD of 0.19 indicates Positive momentum. The RSI at 59.99 is Neutral, neither overbought nor oversold. The STOCH value of 47.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0241.

Alibaba Health Information Technology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6618	76 Outperform	HK$201.05B	38.88	8.52%	―	18.56%	79.54%
0241	73 Outperform	$88.01B	56.70	9.31%	―	12.02%	40.17%
Sector *	51 Neutral	$7.85B	-0.21	-41.41%	2.22%	22.81%	-2.01%
PANHF	―	$5.73B	169.35	1.37%	59.37%	―	―
2696	70 Outperform	HK$42.34B	47.57	27.37%	―	2.57%	18.79%
2367	62 Neutral	HK$57.05B	22.67	29.64%	1.22%	36.70%	22.26%
1952	46 Neutral	HK$22.30B	―	-15.75%	―	102.73%	38.42%

Alibaba Health Information Technology Corporate Events

Alibaba Health Revises Annual Caps and Renews Cloud Services Agreement

Alibaba Health Information Technology Limited announced revisions to its annual caps for the 2025–2027 Platform and Software Services Framework Agreements, citing insufficient original caps to meet business needs. Additionally, the company renewed its Cloud Computing Services Framework Agreement for 2026–2027, ensuring continued collaboration with Alibaba Cloud. These strategic adjustments aim to align with business growth and compliance with listing rules, reinforcing Alibaba Health’s operational capabilities and market positioning.

Alibaba Health Grants RSUs to Boost Employee Retention

Alibaba Health Information Technology Limited announced the grant of 1,095,200 Restricted Share Units (RSUs) to certain employees under the 2024 Share Award Scheme. The RSUs are designed to incentivize employees by providing them equity interests in the company, aligning their efforts with the company’s growth and development. These RSUs will vest over a period of two to four years and are not tied to performance targets, reflecting the company’s strategy to retain talent and encourage long-term commitment. This move is expected to strengthen employee loyalty and support the company’s expansion goals.